ストックスクリーナーアプリを入手
1.19
1.71%
0.02
アフターアワーズ：
1.19
Plus Therapeutics Inc (PSTV) 最新ニュース
Earnings call: Plus Therapeutics reports progress and financials for Q3 2024 - Investing.com
Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance
Plus: Q3 Earnings Snapshot - Houston Chronicle
Plus Therapeutics Advances Radiotherapeutics in Q3 2024 - TipRanks
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
PLUS THERAPEUTICS Inc (PSTV) Quarterly 10-Q Report - Quartzy
Leptomeningeal Metastases Clinical Trials 2024: FDA - openPR
Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics - Seeking Alpha
Sitravatinib Plus Nivo-Ipi Appears Safe, Active in ccRCC - Cancer Therapy Advisor
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Plus Therapeutics partners with SpectronRx for cancer therapy - Investing.com India
Plus Therapeutics partners with SpectronRx for cancer therapy By Investing.com - Investing.com UK
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership - GlobeNewswire
Plus Thera teams up with SpectronRx for radiotherapy production - The Pharma Letter
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024 - GlobeNewswire
Plus Therapeutics (PSTV) Sets Q3 2024 Earnings Call for November 14 | PSTV Stock News - StockTitan
Plus Therapeutics granted extension by Nasdaq - Investing.com
Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail
Plus Therapeutics Showcases Leptomeningeal Metastases - GlobeNewswire
Simulations Plus, Inc. (NASDAQ:SLP) Receives $56.00 Consensus Price Target from Analysts - Defense World
Metastatic Colorectal Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Daiichi Sankyo Company, Mirati Therapeutics, Apollomics - Barchart
Evaluating Immunotherapy as Systemic Therapy Plus RT in Early-Stage NSCLC - Cancer Network
Colorectal Cancer Pipeline Overview 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa Pharma - The Globe and Mail
Curio Digital Therapeutics Applauded by Frost & Sullivan for Enhancing Women's Maternal Mental Healthcare with its MamaLift and MamaLift Plus Solutions - The Malaysian Reserve
Prescription Digital Therapeutics for Mental Health: A New Era in Psychiatry - Psychiatry Advisor
SalioGen Therapeutics hit by layoffs, as gene-editing biotechs continue to struggle - STAT
Ultra-Hypofractionated Radiation May Mitigate Breast Cancer Recurrence - Cancer Network
Plus Therapeutics reports progress in brain cancer trial - Investing.com
Plus Therapeutics reports progress in brain cancer trial By Investing.com - Investing.com Canada
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting - ForexTV.com
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update - GlobeNewswire
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of ... - The Bakersfield Californian
Dow Tumbles Over 200 Points; Carnival Posts Upbeat Earnings - Benzinga
The 3 Best Light Therapy Lamps of 2024 | Reviews by Wirecutter - Wirecutter, A New York Times Company
Celldex drug reduces chronic hive activity, but patient discontinuations raise questions - STAT
Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease - Frontiers
Elevar Therapeutics Resubmits New Drug Application to FDA - GlobeNewswire
Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma Boosted by CARES-310 Leading Overall Survival Analysis - Yahoo Finance
Bluejay Diagnostics (NASDAQ:BJDX) versus Plus Therapeutics (NASDAQ:PSTV) Head-To-Head Review - Defense World
Plus Therapeutics to present at CNS Annual Meeting By Investing.com - Investing.com Canada
From 'science fiction to reality': New George Church-founded biotech raises $75M for cell therapy platform - Fierce Biotech
Plus Therapeutics to present at CNS Annual Meeting - Investing.com
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 - GlobeNewswire
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting - StockTitan
Gilead Sciences Therapeutic Areas: Virology, Oncology & Inflammation - Gilead Sciences
Plus Therapeutics director buys $6k worth of shares By Investing.com - Investing.com Canada
Plus Therapeutics director buys $6k worth of shares - Investing.com
Plus Therapeutics director acquires $8.5k in stock - Investing.com
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):